Patient-Derived Xenograft Models for Endometrial Cancer Research

被引:34
作者
Moiola, Cristian P. [1 ,2 ]
Lopez-Gil, Carlos [2 ]
Cabrera, Silvia [3 ]
Garcia, Angel [4 ]
Tom Van Nyen [5 ]
Annibali, Daniela [5 ]
Fonnes, Tina [6 ]
Vidal, August [7 ,8 ]
Villanueva, Alberto [8 ,9 ]
Matias-Guiu, Xavier [10 ,11 ,12 ]
Krakstad, Camilla [6 ]
Amant, Frederic [13 ,14 ]
Gil-Moreno, Antonio [2 ,3 ]
Colas, Eva [2 ]
机构
[1] Univ Hosp Arnau de Vilanova, Biomed Res Inst Lleida IRBLLEIDA, Pathol Oncol Grp, Lleida 25198, Spain
[2] CIBERONC, Vall Hebron Inst Res, Biomed Res Grp Gynecol, Barcelona 08035, Spain
[3] Vall Hebron Univ Hosp, Dept Gynecol Oncol, Barcelona 08035, Spain
[4] Vall Hebron Univ Hosp, Dept Pathol, Barcelona 08035, Spain
[5] Katholieke Univ Leuven, Dept Oncol, Gynecol Oncol, B-3000 Leuven, Belgium
[6] Haukeland Hosp, Dept Obstet & Gynecol, N-5021 Bergen, Norway
[7] Univ Hosp Bellvitge, Dept Pathol, CIBERONC, Oncobell,IDIBELL, Barcelona 08907, Spain
[8] Xenopat SL, Business Bioincubator, Bellvitge Hlth Sci Campus, Barcelona 08907, Spain
[9] Catalan Inst Oncol ICO, Chemoresistance & Predict Factors Lab, IDIBELL, ProCURE,Oncobell, Barcelona 08908, Spain
[10] Univ Lleida, Univ Hosp Arnau de Vilanova, Pathol Oncol Grp, Lleida 25198, Spain
[11] Univ Lleida, Univ Hosp Arnau de Vilanova, Dept Pathol, Lleida 25198, Spain
[12] Univ Hosp Bellvitge, IRBLLEIDA, IDIBELL, CIBERONC, Barcelona 08907, Spain
[13] Antoni Van Leeuwenhoek Netherlands Canc Inst AvL, CGOA, NL-1066 CX Amsterdam, Netherlands
[14] UMC, NL-1066 CX Amsterdam, Netherlands
关键词
orthoxenograft; uterine cancer; avatar; murine models; personalized medicine; targeted therapy; preclinical studies; translational research; TUMOR XENOGRAFTS; PRECISION MEDICINE; MURINE MODELS; AKT INHIBITOR; MOUSE MODELS; IN-VITRO; GROWTH; PALBOCICLIB; METASTASIS; GENERATION;
D O I
10.3390/ijms19082431
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Endometrial cancer (EC) is the most common malignancy of the genital tract among women in developed countries. Recently, a molecular classification of EC has been performed providing a system that, in conjunction with histological observations, reliably improves EC classification and enhances patient management. Patient-derived xenograft models (PDX) represent nowadays a promising tool for translational research, since they closely resemble patient tumour features and retain molecular and histological features. In EC, PDX models have already been used, mainly as an individualized approach to evaluate the efficacy of novel therapies and to identify treatment-response biomarkers; however, their uses in more global or holistic approaches are still missing. As a collaborative effort within the ENITEC network, here we describe one of the most extensive EC PDX cohorts developed from primary tumour and metastasis covering all EC subtypes. Our models are histologically and molecularly characterized and represent an excellent reservoir of EC tumour samples for translational research. This review compiles the information on current methods of EC PDX generation and their utility and provides new perspectives for the exploitation of these valuable tools in order to increase the success ratio for translating results to clinical practice.
引用
收藏
页数:17
相关论文
共 75 条
[71]   Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer [J].
Weroha, S. John ;
Becker, Marc A. ;
Enderica-Gonzalez, Sergio ;
Harrington, Sean C. ;
Oberg, Ann L. ;
Maurer, Matthew J. ;
Perkins, Sarah E. ;
AlHilli, Mariam ;
Butler, Kristina A. ;
McKinstry, Sarah ;
Fink, Stephanie ;
Jenkins, Robert B. ;
Hou, Xiaonan ;
Kalli, Kimberly R. ;
Goodman, Karin M. ;
Sarkaria, Jann N. ;
Karlan, Beth Y. ;
Kumar, Amanika ;
Kaufmann, Scott H. ;
Hartmann, Lynn C. ;
Haluska, Paul .
CLINICAL CANCER RESEARCH, 2014, 20 (05) :1288-1297
[72]   Molecular imaging in drug development [J].
Willmann, Juergen K. ;
van Bruggen, Nicholas ;
Dinkelborg, Ludger M. ;
Gambhir, Sanjiv S. .
NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (07) :591-607
[73]   The allosteric AKT inhibitor, MK2206, decreases tumor growth and invasion in patient derived xenografts of endometrial cancer [J].
Winder, Abigail ;
Unno, Kenji ;
Yu, Yanni ;
Lurain, John ;
Kim, J. Julie .
CANCER BIOLOGY & THERAPY, 2017, 18 (12) :958-964
[74]   Endometrial carcinoma: molecular alterations involved in tumor development and progression [J].
Yeramian, A. ;
Moreno-Bueno, G. ;
Dolcet, X. ;
Catasus, L. ;
Abal, M. ;
Colas, E. ;
Reventos, J. ;
Palacios, J. ;
Prat, J. ;
Matias-Guiu, X. .
ONCOGENE, 2013, 32 (04) :403-413
[75]   In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor [J].
Yu, Yi ;
Hall, Terence ;
Eathiraj, Sudharshan ;
Wick, Michael J. ;
Schwartz, Brian ;
Abbadessa, Giovanni .
ANTI-CANCER DRUGS, 2017, 28 (05) :503-513